Zugänglichkeit
Animation
Zugänglichkeit
Medicines may be priced freely for up to one year following marketing authorisation. However, a benefit dossier must still be submitted to the G-BA at launch. All medicines with marketing authorisation are reimbursed; however, the reimbursement level is based on "additional benefit" determined by the G-BA and negotiated with GKV-SpV. Patients must pay the difference between the reimbursement level and the sale price.